Novo Nordisk

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Beta Bionics, a medical technology company, developed the iLet Bionic Pancreas for people with type 1 diabetes. It is an automated system that can deliver insulin in one or two hormone modes, automatically calculating and administering all insulin doses needed. The FDA-approved iLet Bionic Pancreas eliminates traditional setup, carbohydrate counting, correction, and bolus calculation.&nbsp;The system is compatible with two continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM. It is a pocket-sized, wearable medical device that uses ML algorithms to control blood sugar levels in people with diabetes. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a dual-hormone bionic pancreas.Key customers and partnershipsThe company has collaborated with pharmaceutical companies to improve its lead technology:&nbsp;<a href="https://www.betabionics.com/zealand-and-beta-bionics-to-collaborate-on-the-development-of-a-first-in-class-dual-hormonal-bionic-pancreas-system-for-treatment-of-people-with-type-1-diabetes/">Zealand Pharma</a> (June 2016) to develop a new dual-hormonal artificial pancreas system for the treatment of diabetes and&nbsp;<a href="https://www.betabionics.com/beta-bionics-and-convatec-announce-partnership-to-bring-unomedical-infusion-set-portfolio-to-the-ilet-bionic-pancreas-system/">ConvaTec</a> (July 2019) to manufacture infusion sets for use with Beta Bionics' iLet Bionic Pancreas System, which autonomously controls blood sugar levels in people with diabetes.&nbsp;

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. The company’s technology integrates with over 200 diabetes and biometric devices worldwide, offering the largest compatibility among connected care platforms.Glooko’s FDA-approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices. The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app.In <a href="https://sp-edge.com/updates/9200?industryIds=22">March 2022</a>, Glooko acquired Paris-based DIABNEXT, a diabetes care platform, and rebranded it as Glooko XT for the French market. Furthermore, in <a href="https://sp-edge.com/updates/8154">January 2022</a>, Glooko acquired Berlin-based xbird, a medical AI company developing solutions for predicting health risks and supporting diabetes management through personalized interventions.Key customers and partnershipsAs of October 2024, Glooko had partnered with more than 8,000 clinics and served 4.4 million users with diabetes across 30 countries.&nbsp;The company has established several key partners, including 1) <a href="https://www.hedia.com/hedia-and-glooko-reveal-new-global-partnership/">Hedia</a> to integrate Hedia's insulin dosing algorithm into Glooko's platforms (June 2023), 2) <a href="https://sp-edge.com/updates/25233">Better Therapeutics</a> to integrate Better Therapeutics' AspyreRx into Glooko's platform (January 2024), and 3) Sanofi to integrate Sanofi's SoloSmart device into the Glooko platform (February 2023).

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Ventus Therapeutics develops novel therapeutics for various therapeutic areas including autoimmune diseases, neurological disorders, and inflammation. The company&rsquo;s approach is based on exploring unknown or poorly understood binding pockets on protein surfaces and screening billions of compounds to identify small molecules suitable to match the pockets. To do this, it leverages its AI-powered computational drug discovery platform, ReSOLVE, which combines structural biology, protein science, and chemistry capabilities.
 
 
 As of March 2024,Ventus had three drug candidates in its pipeline, namely 1) VENT-03, a cGAS inhibitor; 2) VENT-02, a brain-penetrant NLRP3 inhibitor; and 3) VENT-01, a systemic NLRP3 inhibitor. The company has advanced VENT-02 and VENT-03 into Phase I clinical trials.&nbsp;
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://mila.quebec/en/ventus-mila/">
 November 2022
 </a>
 , the company partnered with Mila, an AI research institute, to integrate advanced machine-learning capabilities into the ReSOLVE platform. Further, in 
 <a href="https://www.ventustx.com/ventus-therapeutics-enters-exclusive-development-and-license-agreement-with-novo-nordisk-for-nlrp3-inhibitor-program/">
 September 2022
 </a>
 , the company partnered with Novo Nordisk to advance its NLRP3 inhibitor program, targeting a range of liver, kidney, and cardiometabolic diseases.
 
 
 Funding and financials
 
 
 In February 2022, Ventus raised USD 140 million in a 
 <a href="https://sp-edge.com/updates/8386">
 Series C 
 </a>
 funding round co-led by Softbank Vision Fund 2 and RA Capital Management. GV (formerly Google Ventures) also participated in the round. The proceeds were earmarked for developing the company&rsquo;s computational platform, advancing its drug pipeline, and establishing proprietary virtual libraries. As of August 2022, Ventus had raised an aggregate of USD 300 million in private funding. 
 
</div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Glooko is an app-based remote patient monitoring and diabetes management platform that collects patient data from a range of third-party glucose monitoring devices. Glooko’s US Food &amp; Drug Administration approved Mobile Insulin Dose Adjustment System (MIDS) allows healthcare providers to create customized care plans and provides patients with daily instructions on recommended insulin dosage levels based on the readings from the glucose monitoring devices.The platform also allows diabetic patients to track activity data and meals, access educational material, and follow care plans that are monitored through the app. As of March 2021, the app has partnered with more than 7,500 clinics and served 3 million users with diabetes across 27 countries.As of March 2022, the company had acquired two companies: 1) <a href="https://sp-edge.com/updates/8154">xbird </a>, a German AI-backed medical company, and 2) French diabetes care platform <a href="https://sp-edge.com/updates/9200?industryIds=22">DIABNEXT </a>as part of its planned global expansion drive. The integration of xbird’s Just In Time Adaptive Intervention technology will enhance Glooko’s advanced analytics capabilities and tools as well as expand its global reach across 7,500 clinics and more than one million users. DIABNEXT will be rebranded as Glooko XT and two platforms will be available for the French market which allow the company to scale its operations into more regions and expand its remote patient monitoring services.As of <a href="https://sp-edge.com/updates/34688">October 2024</a>, more than 4.4 million people worldwide with diabetes have used the Glooko platform.

Reinventing gene therapies with next-generation technologies

Human Gene Editing

<div>
 
 ElevateBio develops novel cell, gene and regenerative therapies by leveraging technologies such as gene editing, Induced Pluripotent Stem Cells (iPSCs), and cell, protein, and vector engineering. It develops its own therapies whilst also offering its technologies to other biotech and pharmaceutical companies to accelerate the drug development process. It also provides manufacturing support to other cell and gene therapy companies through its centralized R&amp;D and manufacturing company BaseCamp, which offers process development services, current Good Manufacturing Practices (cGMP) grade manufacturing of cell and viral vectors such as adeno-associated virus (AAV), and quality assurance.&nbsp;
 
 
 The company&rsquo;s focus lies on spinning out separate entities for specific therapeutic areas or indications, and has thus far disclosed three such spin-outs: 1) AlloVir (in partnership with Baylor College of Medicine) to tackle infectious diseases primarily targeting 12 viruses; 2) HighPassBio (joint venture with gene editing company Fred Hutchinson to prevent relapsing leukemia; 3) Life Edit Therapeutics (wholly owned gene editing company) to target genetic diseases.&nbsp;
 
 
 Life Edit Therapeutics, which was acquired by ElevateBio in 
 <a href="https://www.biospace.com/article/elevatebio-acquires-life-edit-therapeutics-and-its-next-generation-gene-editing-platform/">
 October 2021
 </a>
 , maintains a large database of ribonucleic acid (RNA)-guided nucleases (RGNs), base editors, and Protospacer Adjacent Motifs (PAMs)&mdash;short sequences that support an enzyme to edit a gene&mdash;for greater specificity and broader genome coverage. Life Edit&rsquo;s gene editing platform enables both in vivo (gene editing done inside the body) delivery and ex vivo (gene editing done in a specialized laboratory and returned to the body) engineering.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has entered into a number of partnerships to offer its manufacturing capabilities and BaseCamp services, which include a 10-year partnership with the 
 <a href="https://www.elevate.bio/blogs/massachusetts-general-hospital-and-elevatebio-announce-a-10-year-alliance-agreement-to-utilize-elevatebio-basecamp-to-manufacture-innovative-cell-and-gene-therapies">
 Massachusetts General Hospital
 </a>
 (July 2019) and a five-year collaboration with the 
 <a href="https://www.elevate.bio/blogs/boston-childrens-hospital-and-elevatebio-announce-five-year-cell-and-gene-therapy-collaboration">
 Boston Children&rsquo;s Hospital
 </a>
 (June 2021) and 
 <a href="https://www.globenewswire.com/news-release/2020/11/10/2123755/0/en/TCR-Therapeutics-Announces-Partnership-with-ElevateBio-to-Expand-TC-210-Manufacturing-Capacity.html">
 TCR2 Therapeutics
 </a>
 (November 2020).
 
 
 Most recently, ElevateBio partnered with 
 <a href="https://sp-edge.com/companies/243071">
 Xcell Biosciences
 </a>
 in January 2024 to develop cell and gene therapies. Through the partnership, ElevateBio became the first member of Xcellbio&rsquo;s beta program for its new AVATAR Foundry device. In addition, Michael Paglia, Chief Technology Officer at ElevateBio&rsquo;s BaseCamp, joined Xcellbio&rsquo;s Scientific Advisory Board. Further, ElevateBio BaseCamp scientists gained access to Xcellbio&rsquo;s AVATAR incubator system for cell therapy research and development as well as two new platforms: the AVATAR Ai system for measuring the potency of cell therapies and the AVATAR Foundry system for cGMP cell therapy manufacturing.
 
 
 ElevateBio also partnered with 
 <a href="https://sp-edge.com/companies/898118">
 Kyverna Therapeutics
 </a>
 in September 2023 to advance a CAR-T platform. Through the partnership, the companies agreed to expand process development and production of Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies. 
 
 
 In February 2023, ElevateBio&rsquo;s subsidiary, Life Edit Therapeutics, partnered with 
 <a href="https://sp-edge.com/updates/16598">
 Moderna Therapeutics
 </a>
 to develop novel therapeutics for genetic and other diseases. Soon after, Life Edit entered a partnership with 
 <a href="https://sp-edge.com/updates/18837">
 Novo Nordisk
 </a>
 in May 2023 to develop novel base-editing treatments for a number of diseases.
 
 
 Funding and financials
 
 
 In a 
 <a href="https://sp-edge.com/updates/18837">
 Series D
 </a>
 funding round in May 2023 led by the AyurMaya Capital Management Fund, ElevateBio raised USD 401 million to fuel the development of its gene-editing platforms and to support its expansion plans. This round followed the company&rsquo;s substantial USD 525 million 
 <a href="https://techcrunch.com/2021/03/15/elevatebio-raises-525m-to-advance-its-cell-and-gene-therapy-technologies/">
 Series C
 </a>
 round in March 2021, bringing the total funds raised to date to USD 1.2 billion.
 
</div>

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. The company is creating next-generation cell therapies by applying its full-stack tissue therapeutic platform, which combines proprietary bioprinting technology, computational tissue design, therapeutic cells, and biomaterials. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological functions inside the body to treat serious metabolic and endocrine diseases such as type one diabetes, obesity, and liver disease.
Aspect partnered with Novo Nordisk in a landmark USD 2.6 billion collaboration to develop bioprinted tissue therapeutics for diabetes and obesity. The company also secured a USD 2.2 million cancer drug development project with collaborators like Merck, GSK, and McGill University in June 2019 to create 3D bioprinted tissues for assessing anti-cancer drug efficacy. Aspect collaborated with Maastricht University to develop viable 3D bioprinted kidney tissue for medical testing, utilizing its RX1 bioprinter.
In July 2024, Aspect announced a USD 200 million project backed by a USD 72.75 million investment from the Canadian and British Columbian governments. This multi-year initiative aims to establish a world-leading clinical biomanufacturing facility, advance Aspect's technology platform, and expand its therapeutic pipeline.

Preserving aquatic life for future generations

Sustainable Aquaculture

Sundew is a Dutch-Danish biotech company founded in 2018 that develops environmentally friendly solutions for aquatic pests, diseases, and invasive species, with a primary focus on the aquaculture industry. The company's flagship product, Biokos, is designed to treat ichthyophthiriasis, also known as "white spot" disease, a major parasitic infection affecting freshwater fish. Biokos utilizes a naturally occurring bacterial compound that targets the parasite without harming fish or other beneficial aquatic organisms. This lipopeptide-based treatment destabilizes the cell membranes of the parasite, making them leaky and ultimately killing the organism.
Sundew's technology platform involves optimizing the fermentation process to increase production of the active compound by the bacteria. The company has conducted extensive testing on the efficacy and safety of its product, including in vivo experiments on infected laboratory fish. In August 2020, Sundew began scaling up production at Alfa-Laval Innovation House in Søborg, Denmark, using 5,000-liter fermentation tanks for pilot production experiments.
In November 2021, Sundew acquired MicroSynbiotiX, an Irish biotech startup, in an all-share transaction. This acquisition added an algal RNA platform to Sundew's portfolio, allowing for the development of oral vaccines for fish that can be delivered through microalgae mixed with fish feed. This complementary technology aims to address viral diseases in aquaculture, such as white-spot disease in shrimp, which causes significant economic losses in the industry.
Key customers and partnerships
Sundew's initial target market is ornamental fish and aquarium enthusiasts, as the regulatory process for this sector is less stringent than for food fish. However, the company's long-term goal is to enter the aquaculture market for edible fish. Sundew has expressed particular interest in the Chinese market, which dominates global freshwater fish production.
The company has collaborated with the University of Copenhagen and the Netherlands Institute of Ecology (NIOO-KNAW) to develop its technology. In September 2019, Sundew was selected for the StartLife Accelerate program, securing EUR 35,000 in funding with an additional EUR 50,000 in the pipeline. The company also received a grant of EUR 780,000 from the Danish government's Green Development and Demonstration Programme (GUDP). In November 2021, Sundew raised EUR 1.4 million in equity and convertible loan funding from The Yield Lab Europe and The Danish Growth Fund (Vaekstfonden) to support its commercialization efforts.

Eikonizo is developing life-changing treatments by producing brain-penetrant small compounds and utilizing in vivo target engagement approaches to speed therapeutic discovery.

Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.

ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases. Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017.

Aspect Biosystems is a biotechnology company developing bioprinted tissue therapeutics to transform how we treat disease. By combining its proprietary microfluidic 3D bioprinting technology, therapeutic cells, and materials science, Aspect is creating a pipeline of allogeneic cell-based tissue therapeutics to replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine.

The Sabi is a community-driven holistic beauty brand that empowers women from conception to postpartum, menopause, and everyday hormonal woes.

Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies, Amalgam Rx has built an innovative platform for rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 5 billion RWE data points utilized by patients and providers on three continents. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com.

Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Ventus' structural immunology platform offers unprecedented insight into mechanisms and molecular structures, combining core capabilities for precisely targeting the innate immune system: proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. Ventus has built an emerging pipeline of multiple drug programs addressing key targets in the innate immune system.

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.

Glooko develops a remote patient-monitoring platform to identify at-risk patients with diabetes. It integrates with diabetes devices, fitness wearables, and activity trackers to allow data capture and provide reports and analytics that aim to drive behavior change and outcomes. The platform not only syncs diabetes data but also enhances communication between individuals with diabetes and their healthcare providers, leading to improved health outcomes. Glooko is available on both Android and iOS, providing users with the ability to track their diabetes data on their smartphones.

Sundew is a biotechnology company that provides biological services for the treatment of aquatic pests and diseases. The company was founded in 2018 and is headquartered in Copenhagen,

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.  The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.  The Companyâ€™s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy.  The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.  The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.

<div> Novo Nordisk A/S (CPH: NOVO-B) is a global healthcare company headquartered in Denmark, with a history dating back over 100 years. The company is a leader in diabetes care and has expanded its focus to include obesity, rare blood disorders, and rare endocrine diseases. Novo Nordisk's product portfolio includes: <ul> <li> Diabetes treatments: Insulins (e.g. Levemir, NovoLog/NovoRapid), GLP-1 receptor agonists (e.g. Victoza) </li> </ul> <ul> <li> Obesity treatments: Wegovy (semaglutide) </li> </ul> <ul> <li> Rare blood disorder treatments </li> </ul> <ul> <li> Rare endocrine disease treatments </li> </ul> <ul> <li> Digital health solutions for diabetes management </li> </ul> In 2023, Novo Nordisk reported sales of DKK 232.3 billion, a 36% increase at constant exchange rates. The company's growth was primarily driven by its GLP-1 based diabetes and obesity treatments, particularly Wegovy. Novo Nordisk is expanding its production capacity to meet increasing demand for its products. The company is also advancing its research pipeline, including developing oral versions of its treatments and exploring new therapeutic areas such as cardiovascular disease. </div>

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Companies that develop engineered proteins that can target specific proteins or cells in the body

Companies that develop large molecules that can be used to target specific RNA molecules in the body, either to silence or replace them

Companies that develop large molecules that combine the targeting ability of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs

Companies that develop large molecules that can be used to replace or supplement deficient or malfunctioning proteins in the body

Companies specializing in peptide-based treatments leverage short amino acid chains, known as peptides, to target and modulate various biological processes for therapeutic applications

RNA Therapeutics

Companies developing treatments using molecules like antisense oligonucleotides (ASOs) and phosphorodiamidate morpholino oligomers (PMOs). These molecules target specific genes to treat genetic diseases by either silencing or modifying gene expression.

Companies using RNA interference (RNAi) to target and silence specific genes involved in diseases for treating various conditions by blocking harmful gene activity.

Companies involved in altering RNA molecules to modify gene expression or correct genetic defects. This can include substitutions, insertions, or deletions of nucleotides, leading to alterations in the RNA sequence and the regulation of RNA molecules to control gene expression or cellular functions.

Companies focused on other RNA-based therapies using approaches such as tRNA, circRNA, lncRNA, and saRNA to develop treatments targeting specific RNA molecules to regulate gene expression.

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 Drug discovery company Evotec SE and Novo Nordisk have chosen three preliminary research projects related to cardiometabolic diseases for their LAB eN² drug discovery accelerator program. The projects are from academic institutions including Boston University, Harvard University, Mass General Brigham, and the Joslin Diabetes Center.
 These projects focus on research areas such as inflammation in cardiometabolic illnesses, metabolic disease regulators, and type one diabetes studies. The collaboration also welcomed five new academies into the program. These are the Boston Children's Hospital, Boston University, Johns Hopkins University, Joskin Diabetes Center, and the Icahn School of Medicine at Mount Sinai.
 Successful projects may receive further funding until the IND application stage, with options for Novo Nordisk to extend development and license certain programs. By joining Evotec's integrated R&amp;D platform with Novo Nordisk's expertise in illness, the partnership aims to advance therapeutic candidates across multiple areas.
 </div>

Novo Nordisk

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless